ArticleProstate cancer and prostatic diseases2026

Using patient-reported outcomes from the PROCLAIM trial to assess the impact of universal germline genetic testing for prostate cancer patients.

Neal D Shore et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.